Search

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US

Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.

See our Locations

We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.

Boehringer Ingelheim - Life Forward

Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

She finds purpose in the saddle and pursues a passion for horses – at home and work

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US

Click here to read more on the launch of the new Bovikalc® Dry for Dairy Cows, an oral mineral supplement contributing to well-being for dairy cows.

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Reducing Stress in Horses – With Music

Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US

See our Locations

Boehringer Ingelheim - Life Forward

Interchangeable Biosimilar Now on Express Scripts® Formulary

Low-WAC interchangeable biosimilar is now available

She finds purpose in the saddle and pursues a passion for horses – at home and work

Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Could decentralised trials transform the way we view depression?

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

New agreement with Quallent expands biosimilar access

FDA approves additional formulation of biosimilar

BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Reducing Stress in Horses – With Music

New affordability initiative with GoodRx for our biosimilar

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US